Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: video (2)

CEO Heltzen interviewed by Maxine Hoover at the Beryl Elites’ Investment Conference in New York City
heltzeninvestorpress clippingsvideo
Beryl Elites: What is Artificial Evolution - an interview with CEO HeltzenJanuary 7, 2026
'The Upside' interview: Michael Heltzen & Lou Basenese
heltzeninvestornutraceuticalsmedicinepress clippingsvideoNCTcannabinoids
'The Upside' interview: Michael Heltzen & Lou BaseneseNovember 18, 2025
CSO, Tyler Korman
talentinvestorvideokorman
Co-founder of eXoZymes and cell-free biomanufacturing pioneer, Tyler Korman, speaks to his new role as CSONovember 13, 2025
CEO, Michael Heltzen is interviewed by Jane King
heltzeninvestorpress clippingsvideo
Jane King interviews CEO, Michael Heltzen, in New YorkNovember 12, 2025
Tyler Korman: How is eXoZymes uniquely positioned to take advantage of AI?
videosciencekorman
Tyler Korman: How is eXoZymes uniquely positioned to take advantage of AI?November 11, 2025
Podcast: 'The Catalyst' interviews CEO, Michael Heltzen
heltzenpress clippingsvideopodcast
Podcast: 'The Catalyst' interviews CEO, Michael HeltzenOctober 17, 2025
Zachary Karl, Vice President Business Development @ Bio Innovations Midwest 2025
press clippingsvideo
World Bio Markets: AI - A tool U.S. industrial biomanufacturing cannot ignoreOctober 8, 2025
Inside Biotech podcast interviews CEO, Michael Heltzen
heltzenpress clippingsvideopodcast
Podcast: 'Inside Biotech' interviews CEO, Michael HeltzenOctober 2, 2025
MDB Capital: eXoZymes & NCTx: The Breakthrough Opportunity with NCTx and Treating a Global Health Epidemic
heltzeninvestorpress clippingsvideo
MDB Capital: eXoZymes & NCTx: The Breakthrough Opportunity with NCTx and Treating a Global Health EpidemicSeptember 18, 2025
The challenges of SynBio
video
The challenges of SynBioSeptember 15, 2025
Previous page
Page 2 of 5
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark